Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Fisogatinib |
Synonyms | |
Therapy Description |
Fisogatinib (BLU-554) binds to and inhibits FGFR4 (a receptor for FGF19), potentially resulting in decreased proliferation of FGFR4 and FGF19-expressing tumor cells (PMID: 29547556, PMID: 31575540, PMID: 31575541). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Fisogatinib | BLU554|BLU-554 | FGFR4 Inhibitor 9 | Fisogatinib (BLU-554) binds to and inhibits FGFR4 (a receptor for FGF19), potentially resulting in decreased proliferation of FGFR4 and FGF19-expressing tumor cells (PMID: 29547556, PMID: 31575540, PMID: 31575541). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02508467 | Phase I | Fisogatinib | A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma | Completed | USA | ITA | GBR | FRA | ESP | DEU | CHE | 5 |